dc.contributor.author |
Jaafar, Iman |
dc.contributor.author |
Atallah, David M. |
dc.contributor.author |
Mirza, Fadi Ghazi |
dc.contributor.author |
Abu-Musa, Antoine A. |
dc.contributor.author |
El-Kak, Faysal H. |
dc.contributor.author |
Seoud, Muhieddine A.F. |
dc.date.accessioned |
2025-01-24T12:08:12Z |
dc.date.available |
2025-01-24T12:08:12Z |
dc.date.issued |
2022 |
dc.identifier.uri |
http://hdl.handle.net/10938/31754 |
dc.description.abstract |
Objective: To improve the knowledge, awareness, and attitude (KAA) among health care providers (HCPs) regarding Human Papilloma Virus vaccination (HPV-V), the Lebanese Society of Obstetrics and Gynecology (LSOG) has regularly organized educational meetings, symposia, and workshops. Methods: We conducted two sets of surveys among attendees of the LSOG congresses in 2009 and 2018 to assess their KAA towards HPV-V. Results: Around 30% (362) of LSOG attendees participated in our surveys in 2009 and 2018 (185 Vs.177 respectively). Most of them were obstetricians and gynecologists. Most HCPs considered that HPV-V can prevent cervical cancer (CC) [82% and 80% respectively, P = 0.73], however, around 60% were confident enough to convince their patients. HCPs who were confident about the efficacy of the HPV-Vs were more likely to believe that HPV-V can prevent CC (odds ratio = 22.5, p-value = 0.003). These HCPS were more likely to recommend HPV-V (OR = 6.6, p-value = 0.009). About 20% of HCPs who usually recommend HPV-V, reported cost as a main barrier compared to 76% of those who did not. Conclusions: Being familiar with HPV, HPV-related diseases, CC, HPV vaccines and their effectiveness significantly influence whether a HCP recommends HPV-V. The KAA of HCPs did not significantly improve from 2009 to 2018. © 2022 The Author(s) |
dc.language.iso |
en |
dc.publisher |
Elsevier B.V. |
dc.relation.ispartof |
Clinical Epidemiology and Global Health |
dc.source |
Scopus |
dc.subject |
Attitude |
dc.subject |
Health personnel |
dc.subject |
Knowledge |
dc.subject |
Lebanon |
dc.subject |
Papillomavirus vaccines |
dc.subject |
Human papilloma virus vaccine |
dc.subject |
Adult |
dc.subject |
Aged |
dc.subject |
Article |
dc.subject |
Child |
dc.subject |
Clinical article |
dc.subject |
Comparative study |
dc.subject |
Female |
dc.subject |
General practitioner |
dc.subject |
Gynecologist |
dc.subject |
Health care cost |
dc.subject |
Health care personnel |
dc.subject |
Human |
dc.subject |
Lebanese |
dc.subject |
Male |
dc.subject |
Middle aged |
dc.subject |
Obstetrician |
dc.subject |
Papillomavirus infection |
dc.subject |
Pediatrician |
dc.subject |
Serotype |
dc.subject |
Uterine cervix cancer |
dc.subject |
Vaccination |
dc.title |
Determinants of Human Papillomavirus Vaccine recommendation among Middle Eastern and Lebanese Healthcare Providers |
dc.type |
Article |
dc.contributor.department |
Obstetrics and Gynecology |
dc.contributor.faculty |
Faculty of Medicine (FM) |
dc.contributor.institution |
American University of Beirut |
dc.identifier.doi |
https://doi.org/10.1016/j.cegh.2022.101092 |
dc.identifier.eid |
2-s2.0-85136568993 |